Phorm Reports on Agreement with Boston Globe Media Group
Phorm's cutting-edge Machine-Learning Artificial Intelligence ("AI") technology makes it easier and more efficient for publishers (and other sellers of advertisements) to identify and target specific audiences and extend audience reach to ultimately achieve more successful advertising campaigns. The Company's proprietary technology also provides unrivaled insight into digital advertising supply and demand dynamics such that publishers can regain more control of their advertising inventory.
Recognising the potential value and benefits of Phorm's software platform, Boston Globe will implement Phorm' technology across its digital properties to seek and achieve increased advertising sales and performance as well as optimised inventory control.
Boston Globe, through its developing relationship with Phorm, will continue to seek to extend its circa 4 - 5 million unique visitors per month, increase its advertising revenues through new sources, and optimise the revenue potential of all third party partnerships that it is working with, including Phorm.
Commenting on Boston Globe's decision to implement Phorm's platform, Pete Doucette, VP of Consumer Sales & Marketing, said:
"We are always looking to increase our revenue and margin, and engage with new users across our various websites and media channels. Phorm's technology will enable us to identify users in a deeper and more meaningful manner during their consumer journey with us and other sites, with an overarching objective of increasing our potential share of advertising spend."
Phorm's CEO, Timothy Smith, added:
"We're most energised and excited to be working with such a nationally esteemed brand as the Boston Globe, which is innovating through the use of technology. We are looking forward to demonstrating the power of our technology software platform and contributing to Pete and his team's enhanced understanding of their audience, delivering users more efficiently and recruiting new users of Boston Globe's content."




Комментарии